25112-95-2

Basic information

• Product Name: toluene-4-sulfonic acid 2-(3-methoxyphenyl)-ethyl ester
• Synonyms: toluene-4-sulfonic acid 2-(3-methoxyphenyl)-ethyl ester
• CAS NO: 25112-95-2
• Molecular Weight: 306.383
• Mol File: 25112-95-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 37.5-38.5 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
• Boiling Point: 463.2±33.0 °C(Predicted)
• Density: 1.201±0.06 g/cm3(Predicted)
• CAS DataBase Reference: toluene-4-sulfonic acid 2-(3-methoxyphenyl)-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: toluene-4-sulfonic acid 2-(3-methoxyphenyl)-ethyl ester(25112-95-2)
• EPA Substance Registry System: toluene-4-sulfonic acid 2-(3-methoxyphenyl)-ethyl ester(25112-95-2)

Safety Data

• Hazardous Substances Data: 25112-95-2(Hazardous Substances Data)

Upstream product

• 5020-41-7 2-(3-methoxyphenyl)-ethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 1798-09-0 m-methoxyphenylacetic acid 
• 18927-05-4 methyl (3-methoxyphenyl)acetate 

Downstream Products

• 73004-96-3 1-(2-chloroethyl)-3-methoxybenzene 
• 1208110-65-9 6-methoxy-1'-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one 
• 1208110-16-0 6-methoxy-1'-(2-phenylpropyl)-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208109-86-7 6-methoxy-1'-[2-(2-methylphenyl)ethyl]-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208109-85-6 1'-[2-(4-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208110-63-7 1'-[2-(4-fluoro-2-methylphenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208110-26-2 (2RS)-6-hydroxy-1'-[2-(2-methylphenyl)ethyl]-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one 
• 1208110-40-0 (2RS)-N-{1'-[2-(2-methylphenyl)ethyl]-1-oxo-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-6-yl}acetamide 
• 1208110-41-1 (2RS)-1'-[2-(2-methylphenyl)ethyl]-6-phenyl-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208109-94-7 (2R)-6-methoxy-1'-[2-(2-methylphenyl)ethyl]-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208110-27-3 C₂₄H₂₆F₃NO₄S 
• 1208109-99-2 (2S)-1'-[2-(4-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208110-14-8 (2S)-1'-[2-(3-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208110-05-7 (2S)-1'-[2-(2-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 

Relevant articles and documents

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction

Disruption of EZH2-embryonic ectoderm development (EED) protein-protein interaction (PPI) is a new promising cancer therapeutic strategy. We have previously reported the discovery of astemizole, a small-molecule inhibitor targeting the EZH2-EED PPI. Herein, we report the cocrystal structure of EED in complex with astemizole at 2.15 ?. The structure elucidates the detailed binding mode of astemizole to EED and provides a structure-guided design for the discovery of a novel EZH2-EED interaction inhibitor, DC-PRC2in-01, with an affinityKdof 4.56 μM. DC-PRC2in-01 destabilizes the PRC2 complex, thereby leading to the degradation of PRC2 core proteins and the decrease of global H3K27me3 levels in cancer cells. The proliferation of PRC2-driven lymphomas cells is effectively inhibited, and the cell cycle is arrested in the G0/G1 phase. Together, these data demonstrate that DC-PRC2in-01 could be an effective chemical probe for investigating the PRC2-related physiology and pathology and providing a promising chemical scaffold for further development.

A facile total synthesis of ent-17β-estradiol and structurally related analogues

A facile six-step synthesis (15.2% yield) of ent-17β-estradiol from readily accessible precursors is described. The preparation of analogues with 2-alkyl substituents, double bond unsaturation in the C-ring, a cis C,D-ring fusion and modified substituents at C17 is also reported.

New indole derivatives as factor Xa inhibitors

The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.